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Thesis Summary
Colorectal cancer is the fourth most common cancer in the United States (US) and
is estimated to be responsible for 49,190 deaths in this year alone. It is the second leading
cause of cancer deaths in the US is ranked third in prevalence worldwide. Many factors
can increase the risk for colorectal cancer including family history of colorectal cancer,
gender, age, as well as behavioral and lifestyle choices. Most colorectal cancers are
adenocarcinomas and often begin as a polyp, formed in the inner wall of the colon or
rectum and carry no detectable symptoms. It is in this quiet beginning that colorectal
cancer can develop unsuspectingly over a period of 10 to 15 years. When the polyp
begins to invade deeper into to colon or rectum wall it moves closer and closer to the
lymph nodes and the bloodstream that carry the now malignant cells throughout the body,
causing the deadliest stage of cancer; metastasis. It is in prevention that colorectal cancer
can be combated, using colonoscopies or sigmoidoscopies to explore the walls for polyps.
It is also what drives research to improve outcomes, studies to attempt to understand what
causes metastasis and to find therapeutic biomarkers to halt the disease in its tracks.
The first experiments were aimed at determining if a plasmid vector expressing
Lcn2 can be used to increase its serum levels in mice via in vivo electroporation. Since
Lcn2 secretion is vital for this process, the established cell line CT26-luc was transiently
transfected and examined using a western blot. Intracellular and secreted levels of Lcn2
were determined and confirmed, validating both Lcn2’s positive association with
metastatic conditions as well as pV1J’s role as a viable vector for Lcn2 expression and
secretion into circulation during in vivo electroporation.
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The empty vector pV1J and pV1J-Lcn2, expressing Lcn2 were isolated and
purified under endotoxin free conditions at a concentration of 1 ug/uL. 50uL of either
pV1J or pV1J-Lcn2 were used for electroporation into mice. In vivo electroporation was
conducted in mice bearing tumors from MC38 mouse colon adenocarcinoma cell line in
C57Bl/6 mice, 4T breast cancer cells in Balb/c mice, and B16-F10 melanoma cells in
C57B1/6 mice. Mice were bled prior to electroporation (pre-bleed) and then bleed weekly
after electroporation. Gross tumor analysis showed that elevated circulating levels of
Lcn2 caused a significant increase in primary tumor growth and showed some increase in
metastasis. However, further experiments using varying treatments of dosage must be
explored to determine if the metastasis was significantly increased in these orthotopic
mouse models of cancer.
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Abstract
Lipocalin 2 (Lcn2) is a member of the lipocalin family of siderophore-binding
molecules that can mediate iron trafficking. It acts during the innate immune response
and has been implicated in conflicting roles in metastasis, leaving its role undefined. In
breast cancer LCN2 was shown in previous studies to both inhibit or promote metastasis.
Previous studies the Pena laboratory showed that increasing the serum levels of LCN2
caused a significantly increase in liver metastasis of the poorly metastatic MC-38 colon
cancer cell line. In this study, we examined the ability of LCN2 to promote metastasis of
colon and other cancers to the lung to determine its functionality as a multi-organ
determinant of metastatic growth. The effect of elevated circulating levels of LCN2 on
lung metastasis was tested on mouse models using MC-38 colon adenocarcinoma cells,
4T1 breast cancer cells, and B16-F10 melanoma cells using C57B1/6 (B6), Balb/c, and
B6 mice, respectively. Isolated using endotoxin free methods, pV1J-LCN2 plasmid was
utilized for in vivo electroporation of the mice, with the cancerous cells injected using
tail-vein, mammary fat pad, and subcutaneous injections. The empty vector, pV1J was
used as the control. Blood serum and in vivo bioluminescent images were obtained
weekly, along with caliper measurements of the primary tumor. Mice were sacrificed
after three weeks and the lungs, liver, and spleen were weighed and examined for
metastasis post-mortem. Preliminary results indicate that LCN2 promoted a significant
increase in tumor mass in all three cell lines. Though some metastasis was observed,
further studies are required to determine the extent of the metastatic potential of LCN2.
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Introduction

Colorectal Cancer in Humans
In the United States, colorectal cancer (CRC) is the third most common cancer
and the second leading cause of cancer death in men and women.4 It was estimated that in
2016, approximately 136,830 new incidences of CRC will be diagnosed and 50,310
deaths would result from colorectal cancer.16 Commonly diagnosed in older patients,
colorectal cancer begins when healthy cells in the epithelial lining of the colon or rectum
begin to proliferate, forming a mass called a tumor. The tumor most often begins as a
polyp, a noncancerous growth that develops on the inner wall of the colon or rectum that
form as a part of aging.
There are five stages used to diagnose colon cancer. Stage 0, also termed
“carcinoma in situ”, is diagnosed when abnormal cells are found in the innermost layer
(mucosa) of the colon wall.5 The stage is termed “in situ” since the cancer is in the
“original place”, as the Latin term suggests. The next four stages progress as the cancer
spreads deeper into colon, to the surrounding organs, to the lymph nodes, and then finally
to metastasis. Metastasis is involved in cancers that commonly have the poorest
prognosis, and occurs when cancer cells break away from the primary tumor and travel
through the blood or lymph system to form new tumors in other areas of the body.11
Metastasis occurs in multiple steps and often has no symptoms, making it
particularly difficult to diagnose and to treat. Early detection can improve diagnosis; the
five-year survival rate of those with localized stage colorectal cancer is approximately
90%. However, when diagnosed at a later stage after metastasis has occurred, the five-
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year survival rate drops to less than 12%.4 At the time of diagnosis, approximately 32%
of patients already have metastasis, and autopsy results often reveal that as many as 70%
of those with colorectal cancers die from metastasis. Common sites of metastasis for
colorectal cancers include the liver, lung, and peritoneum.11 For patients with metastasis,
nearly 50% have metastasis in the liver, with resection as the only curative treatment
option. One of the known factors to influence metastasis is the epithelial- mesenchymal
transition, or EMT. However, a re-differentiation resembling the mesenchymal-epithelial
transition is detectable in the metastases themselves, suggesting that malignancy is based
on dynamic processes including genetic alterations that are then up regulated by the
tumor microenvironment.3 Understanding the genetic and molecular mechanisms of liver
and lung metastasis is critical to the development of better methods of detection and
treatment that can block metastatic recurrence or progression.

The Pre-Metastatic Niche
Prior to the arrival of metastasizing cells to the target organ, the primary
tumor sends molecular signals to recruit bone marrow derived cells (BMDCs) to the liver
where they create a pre-metastatic niche (PMN). Specifically, the up-regulation of
fibronectin and clustering of bone marrow derived cellular infiltrates coexpressing matrix
metalloproteinases in distant tissues prior to tumor cell arrival appear to be invaluable for
the initial stages of metastasis.10 Thus, these bone marrow-derived hematopoietic
progenitors, especially those that express endothelial growth factor receptor 1, mobilizes
in response to an unknown unique combinations of growth factors produced by the
primary tumor.10 This is crucial for the growth of secondary tumors because the PMN
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provides sites where cancer cells can attach as well as a fertile environment where
metastasizing cells can proliferate.3 Identifying these molecules by parsing out the early
cellular and molecular events in cancer dissemination could provide biomarkers for
diagnosis or therapeutic targets to block metastatic progression.

The Tumor Microenvironment
The landmark paper, The Hallmarks of Cancer8, established six underlying
commonalities in cancer that govern the transformation of benign to malignant cells;
evading apoptosis, self-sufficiency in growth signals, insensitivity to anti-growth signals,
tissue invasion and metastasis, limitless replicative potential, and sustained angiogenesis.
The follow up to that seminal work, The Hallmarks of Cancer: The Next Generation7
found two “emerging hallmarks”, reprogramming of energy metabolism and evading
immune destruction. The paper also found that in addition to the cells, the tumors
themselves provided another layer of complexity to the acquisition of the hallmarks. As
more research is done with these hallmarks, the importance of the tumor
microenvironment is becoming increasingly explored. The tumor microenvironment
includes critical stromal support cells, as well as the surrounding blood vessels, various
bone marrow-derived cells such as mesenchymal stem cells, macrophages and other
immune cells, non-neoplastic cells (infiltrating immune cells, fibroblasts, and endothelial
cells), and the extracellular matrix (ECM).7 The TME can secrete growth factors,
chemokines, cytokines, and reactive oxygen species. Though previously thought to be
recruited by molecular signals from cancer cells, the cells of the tumor microenvironment
are influenced and work with cancer cells to support tumor progression by enhancing the
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growth of the primary tumor as well as directing its metastatic spread to distant organs.12
A large issue in understanding metastasis is in identifying the sets of genes (“metastatic
signatures”) that correspond and appear to orchestrate the establishment of macroscopic
metastases in specific tissues. However, it is almost certainly dependent upon the
establishment of a permissive tumor microenvironment.7 Thus, it is understanding the
establishment of the tumor microenvironment, its features and capabilities, that we can
begin to understand cancer metastasis.

Figure 1. The cells of the tumor microenvironment. Not shown are the premalignant
stages in tumorigenesis, which also have distinctive microenvironments created by the
abundance and characteristics of the assembled cells.7
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Previous Work
Dr. Pena’s lab has conducted a number of experiments exploring liver metastasis
and others with LCN2. In previous studies, members of Dr. Pena’s lab examined changes
in gene expression in the liver microenvironment in tumor bearing mice prior to and after
the arrival of metastasizing cells to the liver using microarray analyses. Studies were
conducted with the goal to identify genes that were activated in the liver by signals from
the primary tumor, whose products were essential for establishing a PMN that will
enhance tumor homing and engraftment, and that were required for supporting tumor
growth upon arrival into the liver. LCN2 was found to be the most abundant mRNA that
was expressed 10-fold higher in pre- metastatic liver and 50-fold higher in metastatic
liver as compared to liver from non-tumor bearing mice. Furthermore, overexpression of
serum levels of LCN2 by intramuscular in vivo electroporation of a plasmid expressing
LCN2 prior to splenic injection of tumor cells (an experimental model of liver metastasis)
significantly increased liver metastasis of a poorly metastatic MC-38 colon cancer cell
line.

Figure 2. Comparison of LCN2 serum levels in LCN2 knockout mice, wild type mice, and
mice that were in vivo electroporated with pV1J-LCN2 or pV1J plasmid. Proteins were
normalized against albumin protein2
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Figure 3. Spleen and liver weights, analyzed four weeks after splenic injections of
2 × 10& MC38 cells in C57BL/6 mice. Mice were injected with 50ug of pV1J-Lcn2 or
pV1J plasmids and electroporated. Increased liver weight in the Lcn2 group indicates an
increase in metastasis2
Lipocalin 2: Its Significance and Role
Lipocalin 2 (Lcn2) is a member of the lipocalin family of siderophore-binding
molecules that can mediate iron trafficking.9 Also known as Neutrophil Gelatinase
Associated Lipocalin (NGAL), Lcn2 is a protein expressed in eptithelial cells and
neutrophils. Lipocalins as a family have a key structural component, a b-barrel with eight
anti parallel strands, creating a structure that easily binds to small hydrophobic molecules
(including hormones, retinoids, and fatty acids).15 It can act during the innate immune
response, sequestering iron that would otherwise be taken up by invasive bacterium. Lcn2
has been implicated in conflicting roles in metastasis, thus its role has yet to be firmly
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established. In breast cancer, Lcn2 was shown to inhibit or promote metastasis, while in
CRC, its expression was inversely correlated with metastatic potential, although its role
might be influenced by its specific location in the tissue.1,14 Lcn2 is over-expressed in
many types of non-microbially- associated cancers including breast, pancreatic, and
ovarian carcinomas.15 Lcn2 also has been shown to have a role in promoting
tumorigenesis, done through enhancing tumor cell survival and proliferation.15 It was
discovered that LCN2 can induce the epithelial to mesenchymal transition (EMT), which
is instrumental to metastasis. In colon cancer specifically, LCN2 was found to promote
EMT through RAC1. Further, it was found that in the up-regulation of LCN2 in a poorly
metastatic colon cancer cell line the authors generated more invasive cells.13 However, an
over-expression of Lcn2 in the aggressive metastatic colon cancer cell line KM12SM
markedly reduced its invasive behavior in vitro and in vivo.13 In an additional study, it
was found that LCN2 expression correlates with aggressive tumor formation in mouse
breast tumor cell lines, with the most aggressive from the 4T1 and 4T07 cells.14 Although
LCN2 is a secreted protein, there have been no in vivo studies examining its impact on
the tumor microenvironment particularly in the target organ of metastases.
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Figure 4. LCN2 expression gathered from the National Cancer Institute’s SAGE
Anatomic Viewer. Data from tissues and cell lines were pooled and relative LCN2
expression was compared between non-neoplastic and neoplastic cells15
Objectives of Study
The goal of this study is to test the hypothesis that elevated circulating levels of
LCN2 can promote metastasis of multiple cancers to the liver and lung by recruitment of
bone marrow derived cells that promote tumor homing, attachment, and growth in the
target organ. We will use in vivo electroporation to increase circulating levels of LCN2
and test its ability to promote lung and liver metastasis of CRC, breast cancer, and
melanoma cells using orthotopic and experimental models of lung and liver metastases.
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Materials and Methods

Presence of Lcn2 in CT26-luc Cell Lines by Western Blotting
Western blot analysis is a widely used technique to detect the presence of
proteins, a process dependent on the antibodies incorporated in the procedure of the blot.
The procedure began by waking up CT26-luc cells, removing from liquid nitrogen and
kept in the 37°C water bath for approximately five minutes. Taking care to keep the vial
sterile, cells were resuspended 10 mL of DMEM with 10% fetal bovine serum (FBS)
after being spun down in the centrifuge. Cells were incubated until they reached 80-90%
confluency and then were transiently transfected with pV1J or pV1J-Lcn2 plasmids for
72 hours. Cells were washed with 5mL of HBSS and then 1 mL of Trypsin was added to
the cells and then placed in the 37°C incubator for 5 minutes. After 5 minutes DMEM
was added and the cells were placed in a 15mL Eppendorf tube and centrifuged at 2000
rpm for 5 minutes. The supernatant was removed and the pellet re-suspended in 5mL of
PBS to was it again, repeating the wash and centrifugation. The final time, the pellet was
re-suspended in 1mL of PBS and then centrifuged at 2000 rpm and 5 minutes. The final
cells were then re-suspended in 200 uL of Mammalian Protein Extraction Reagent adding
1uL of 500X Proteinase Inhibitor. The sample was vortexed and put on ice for 10
minutes, centrifuged at 11,000 rpm for an hour at 4°C. Protein samples were quantified
by the Bradford assay using an Epoch plate reader (Biotek Instruments, Inc Winooski,
VT).
The previous protein concentrations were normalized, and 18uL of that sample
was placed into a PCR tube and the BIOL program was run (putting the sample at 99°C
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for 10 minutes). 10uL of Bio Rad Plus Precision Dual Standards Ladder and 18 uL of
samples are added to wells of a precast Mini-PROTEAN Bio-Rad gel and immersed in
1X SDS Page Buffer. The gel is run at 80V until the sample is through the loading gel,
and then raised to 100V for approximately 60 minutes. Follow the gel electrophoresis the
gel is removed and added to a “sandwich” of filter paper and transfer membrane. This
was then placed into the Semi-Dry Transfer Apparatus, and run at 15V for 1 hours, while
in a cocktail of 0.5g of Bio-Rad Blotting Grade Blocker Nonfat dry milk and 9.5 mL of
PBST. After transfer, 5% milk in PBST was added to the membrane and placed in a
shaker at room temperature for 30 minutes. The antibody against the Lcn2 was used as a
probe, and incubated with the primary antibody overnight at 4°C, washed 4 times with
PBST for 10 minutes each, and the secondary antibody (Bio-Rad EIA Grade Affinity
Purified Rabbit Anti-Goat IgG (H+C)-HRP Conjugate, diluted 1:5000) was added to 2%
BSA solution and incubated at least one hour at room temperature. The membrane was
subsequently washed twice for 5 minutes and twice for 10 minutes in PBST. 1 mL of
each ECL Western Blot Detection reagent was mixed and added to the membrane, later
exposed in the dark room for approximately 30 seconds.

Isolation of pV1J and pV1J-Lcn2
In order to determine the effects of Lcn2 on metastasis and the tumor
microenvironment, plasmid needed to be isolated. pV1J was used as the vector due to its
previous success for optimal gene expression intramuscularly by in vivo electroporation.
Additionally, it had previously been show to be an efficient plasmid to increase
circulating levels of the gene of interest.

16

Figure 5. Map of plasmid pV1J-Lcn2. Lcn2 is constitutively expressed by the CMV
promoter and the plasmid confers Kanamycin resistance to transfected cells.

Bacteria transformed with pV1J and pV1J-Lcn2 DNA were grown overnight in a
starter culture containing 5mL containing Kanamycin. The day following those 5mL
starter cultures were grown overnight with incubation at 37°C, in 1.5L LB containing
Kanamycin. This process enables the cloning of the pV1J vector with Lcn2 DNA, and
the. Clones were selectively grown by the addition of Kanamycin, which the vector is
resistant to. Endotoxin free plasmid isolations for in vivo electroporation were purified
using Qiagen Plasmid Plus Mega Kit following manufacturer’s instructions. Plasmid
concentrations were measured by a spectrophotometer, and concentrated or diluted to a
concentration of 1ug/uL.
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Injection of DNA into Mice by In Vivo Electroporation
Prior to surgery, mice were anesthetized from inhalation of 5% isoflurane in
oxygen, delivered at 1 L/minute, and after approximately 1 minute in the induction
chamber, the concentration was lowered to 2.5% isoflurane in oxygen. After the mice in
the induction chamber were successfully anesthetized, mice were removed individually
shaved in the anterior portion of the thigh, clearing the field for the quadriceps. The
mouse was then placed on the sterile operating table with a nose cone to deliver the 2.5%
isoflurane in oxygen to the mouse in question. Laid on its back, a small incision was
made in the skin just above the knee, and the slit was expanded to expose the quadriceps
muscle. 10 ug of pV1J or pV1J-Lcn2 were injected (by a volume of 10 uL), achieved
while holding the syringe vertically and perpendicular to the muscle and pulling out
afterwards in a twisting motion, preventing loss of plasmid to an area other than the
quadriceps muscle. The BTX Electroporator delivered 5 pulses of 100 volts of electricity
at 50 milliseconds each to the site, allowing the muscle to take in the plasmid and express
Lcn2 to be secreted into the bloodstream. The surgical site was closed by staples and the
mice were monitored to assure surgery did not produce undue stress.

18

Figure 6. Method of in vivo electroporation for varying dosage treatments6
Various Cell and Mouse Types for In Vivo Electroporation
In order to determine the kinetics of Lcn2 expression after electroporation, several
combinations of cell line, cell injection site, and mouse type were used. The MC38 colon
adenocarcinoma cell line was used in a previous experiment to determine kinetics of
Lcn2 within colon cancer. 2 × 10& cells were implanted into the spleen of eight week old
C57BL/6 mice the day following in vivo electroporation of pV1J-Lcn2 plasmid or the
empty pV1J vector. Sera were harvested weekly after electroporation and three weeks
after spleen injection, the mice were humanely sacrificed. The 4T1-rfp-luc breast cancer
cell line was used in Balb/c mice to determine kinetics of Lcn2 within breast cancer. An
initial experiment was conducted with injections of 100,000 4T1 cells into the inguinal
mammary fat pads, in the 4th fat pad on either the left or right side of the mouse. Sera
were harvested weekly after electroporation and four weeks after fate pad injection, the
mice were humanely sacrificed.
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Figure 7. Mouse Mammary Gland Anatomy, Injections made in the 4th mammary fat pad
To determine the kinetics further, the 4T1/Balb C experiment was repeated using 5,000
4T1-rfp-luc cells, injected in the same manner in the same area of the mouse.
Electroporated Bi-weekly, sera were collected on the weeks not containing
electroporation. Mice were humanely sacrificed after 8 weeks of this treatment.
The final exploration of kinetics involved the highly metastatic melanoma cell line in
C57B1/6 mice. Following electroporation, 2 × 10& cells were injected subcutaneously.
Mice were electroporated on days 0 and 14 and sera was collected on days 7, 21, and 28,
as well as prior to experiment. Mice were humanely sacrificed after 4 weeks. In all mouse
treatments, blood samples were obtained from the retro-orbital sinus using capillary
tubes, were centrifuged for 5 minutes to separate red blood cells from blood sera
containing Lcn2, and stored at -80°C for further analysis.

20
Gross Analysis of Tumors
Weekly, mice of all treatments were weighed and their primary tumors measured
by caliper. IVIS (in vivo imaging system involving luciferase) was utilized on a biweekly basis to determine if metastasis had occurred. After the mice were sacrificed,
tumor bearing lungs, liver, and spleens of mice as well as the primary tumors were fixed
in 4% paraformaldehyde. The primary tumor and the spleen were weighed as well.
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Results

Intracellular/Extracellular Lcn2 in CT26-luc Cell Line by Western Blotting

Figure 8: CT26-luc stably expressing high levels of Lcn2

The presence of Lcn2 was confirmed in the stably transfected CT-26-luc cell line
by western blot analysis. The data indicates with the the presence of Lcn2 as compared to
the b-actin control.
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Figure 9. CT26-luc extracellular Lcn2 levels, using DMEM+10% FBS as an additional
control

Since the Lcn2 is also secreted, the extracellular proteins levels in cell culture
media were also analyzed. Western blot analysis of CT-26 transient transfected cells
showed an increased level of LCN2 protein in pV1J-Lcn2 cells as compared to those with
the empty vector. These results validate pV1J as a vector to secrete Lcn2 and enable its
use to increase its circulating levels in the blood, specifically for in-vivo electroporation.
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Gross Analysis of Tumors

Figure 10. Pooled Caliper Data from 4T1 experiment, injected with 100,000 cells in the
Mammary Fat Pad

The results for the initial experiment involving 4T1 cells injected into Balb/c mice
show large increases in tumor growth. Tumor volume was measured via caliper weekly
and calculated using the formula V=(W(2)xL)/2. By Day 28, 41% of pV1J mice (n=12)
and 72% (n=11) of pV1J-Lcn2 had the primary tumor spread from the 4th mammary fat
pad to the 5th. Additionally, preliminary IVIS imaging on Day 28 indicated that 2 of the
pV1J-Lcn2 mice had metastasis near the pleural cavity, possibly to the lungs. Figure 10
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clearly displays that though both mice treated with pV1J and pV1J-Lcn2 show in increase
of tumor volume over time, the pV1J-Lcn2 mice showed significantly more growth.

Figure 11. Tumor Mass, Mass Percentage, and Volume from injection of 5,000 4T1-luc
cells in the Mammary fat pad. Data collected approximately 8 weeks after injection
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The 4T1 mammary fat pad experiment was repeated with a reduction in the initial
tumor injection and had a reduction in the number of electroporations conducted,
broadening the kinetics of the tumor progression. Tumor Volume was determined using
the equation 𝑉 = (𝐿 × 𝑊 , )/2. Tumor mass was measured after mice were humanely
sacrificed, and spleen weight was taken as well. Tumor mass percentage was done by
comparing the mass of the tumor to the mass of the mouse. Of the 12 mice, 6 pV1J and 6
pV1J-Lcn2, 5 pV1J and 5 pV1J-Lcn2 had metastases of some from at the time of the
sacrifice. Figure 11 clearly displays the same trend found in the first 4T1 experiment, that
pV1J-Lcn2 mice have larger tumors in terms of volume, mass, and mass percent.

Figure 12. Tumor Mass and Mass Percentage of B16-F10 Melanoma in B6 mice,
approximately 4 weeks after subcutaneous injection
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The C57B1/6 mice injected with B16 F-10 cells similar results. Of the mice
(n=15) at the end of the experiment, only one had lung metastasis, and that mouse was in
the pV1J-Lcn2 treatment. Spleen masses were also measured, and 42.8 % (n=7) of pV1J
mice had spleens weighing over 0.2 g, as well as 62.5% (n=8) of pV1J-Lcn2 mice had
spleens above that benchmark. Overall, Figure 12 clearly displays a significant difference
in tumor growth between the pV1J and pV1J-Lcn2 mice.
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Discussion/Conclusions
In order to understand cancer’s progression, one must study metastasis. Within
that scope, it is also necessary to determine what factors enable or increase that
metastasis, be it the development of a pre-metastatic niche or the role of the tumor
microenvironment. Regardless, it is of vital importance to attempt to find metastatic
biomarkers to the progression of colon and other cancers to metastatic potential. The
confirmation and detection of such a target protein or molecule would prove to be
invaluable to early screening and treatment. In previous studies exploring the
development of CT26-FL3 cells, a highly metastatic cell line, the gene encoding the
protein Lcn2 was found to be highly expressed in the metastatic live both against other
genes and the transcriptional genome of the sham control group of mice not injected with
CT26-FL3 cells. Previous studies within Dr. Pena’s lab also found LCN2 to be the most
abundant mRNA that was expressed 10-fold higher in pre- metastatic liver and 50-fold
higher in metastatic liver as compared to liver from non-tumor bearing mice.
To explore Lcn2 further, in vivo experiments were conducted using colon, breast,
and skin cancer to determine metastatic potential not only in colon cancer but as a more
general biomarker. A western blot analysis was performed using CT26-luc cells
transiently transfected to determine intracellular and extracellular Lcn2 expression. The
analysis revealed both intracellular Lcn2 as well as extracellular Lcn2, which provides
validation that pV1J vector could be utilized to secrete Lcn2 and enable its use to
increase its circulating levels in the blood, specifically for in-vivo electroporation.
To begin viewing Lcn2 and its effects on metastasis within the living mouse
models, the plasmid pV1J-Lcn2 was constructed, isolated, and purified under large-scale

28
endotoxin free conditions. In vivo electroporation was chosen due to its ability to
continuously express Lcn2 in the bloodstream over extended time period via entry by
stable plasmid. There were 3 types of mouse and three cell lines explored, the previously
validated MC38 colon adenocarcinoma cell line injected into the C57Bl/6 mice, the 4T1
breast cancer cell line injected into Balb/c mice, and the B16-F10 melanoma cell line
injected into C57Bl/6 mice. Mice were electroporated with 10ug of either 10uL of pV1J
plasmid or 10uL of pV1J-Lcn2. The plasmid was injected into the quadriceps muscle and
then released into the blood stream via electroporation at 100V for 50ms. Blood was
collected from the retro-orbital sinus prior to surgery as well as weekly after
electroporation.
Gross analysis of tumor progression show that Lcn2 significantly increases
primary tumor growth in both 4T1 and B16-F10 treated mice. Previous experiments
displayed Lcn2’s ability to significantly increase liver weight in MC38 treated mice as
well. Additionally, Lcn2 was shown in the initial 4T1 treatment with 100,000 cells to
possibly increase lung metastasis, with 2 mice showing luciferase activity near the pleural
cavity, both in the Lcn2 treatment group. Repetition with a much smaller initial injection
of 4T1 cells (5,000) allowed the metastatic potential to be explored further, and though it
showed similar increases in tumor volume as the initial experiment, both pV1J and pV1JLcn2 mice had metastasis in equal measure at the final measure of the experiment. The
B16-F10 melanoma cells progressed rapidly, producing often flat tumors difficult to
measure with the caliper, but at the close of the experiment it was determined that Lcn2
treated mice significantly increased tumor mass and mass percent. Of the mice treated,
only one had a lung metastasis, a pV1J-Lcn2 treated mouse.
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The results confirmed some previous experiments while providing some new
insights as well. Lcn2 clearly has a significant effect on the growth of the primary tumor,
regardless of cell line or mouse type. Additionally, it seems to have some slight
correlation with metastasis to the lung, but no significant data was found. The findings
also confirmed in vivo electroporation as viably method to explore Lcn2 as a metastatic
biomarker.
Future experiments could be conducted to further explore Lcn2 and its metastatic
potential. Sera collected could be analyzed with ELISA to determine the expression of
Lcn2 within the bloodstream in the three treatments of the in vivo experiments above.
Additionally, electroporations of the B16-F10 mice could be explored with a reduction in
initial subcutaneous injection to determine that if the tumor kinetics ran longer if more
metastasis would have occurred. Additionally, the 5,000 cell 4T1 mice could be
sacrificed earlier, or more IVIS images could have been taken to determine whether Lcn2
increases metastasis or if metastasis simply occurred because the treatment ran longer.
Analogous studies also could be preformed with Lcn2 inhibition rather than upregulation, be it Lcn2 gene knockout, silencing Lcn2 by siRNAs, or other methods to
study the absence of Lcn2 in colon, skin, or breast cancer metastasis. To confirm the
results found in this study, Lcn2 inhibition should show a vast decrease in tumor mass
and volume as well as a decrease in metastasis. The identification of Bone Marrow
derived cells in any of the areas of metastasis in the orthotopic mouse model would
provide insight to the tumor microenvironment and its interaction with Lcn2. Future
studies could very well be conducted to determine the role of Lcn2 in the tumor
microenvironment and its molecular interactions within that environment and beyond.
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